ICD code T45.3X5S – Adverse effect of enzymes, sequela

Key takeaways

T45.3X5S is a billable ICD-10-CM code for a lasting condition left by a reaction to a correctly used enzyme drug.

Check the Table of Drugs first, because alteplase, streptokinase and pancrelipase code outside T45.3.

Use the S character once the reaction itself has been treated and a named residual condition remains.

List the residual condition first and T45.3X5S second, since the code never stands alone.

Overdose, a wrong drug or missed doses point to poisoning or underdosing codes instead of T45.3X5S.

ICD-10 code T45.3X5S reports what an enzyme drug reaction left behind

ICD-10 code T45.3X5S reports a condition that lingers after a patient reacted to a correctly used enzyme drug. The reaction itself has already been treated. What remains, such as a persistent skin condition, is the reason for the visit.

The code sits in Chapter 19 of ICD-10-CM, under subcategory T45.3 for enzymes. Here’s the reference data to confirm before a claim goes out.

Which enzyme drugs belong in T45.3, and which ones code elsewhere

T45.3 only covers drugs the ICD-10-CM Table of Drugs files as enzymes. That list is shorter than the name suggests. Hyaluronidase, chymotrypsin, chymopapain and bromelains all code here.

Plenty of enzyme medicines land in other subcategories, so look the drug up before you commit:

• Alteplase and streptokinase are thrombolytics, so their sequela code is T45.615S.
• Pancrelipase is a digestant and codes to T47.5X5S.
• Asparaginase is an antineoplastic drug and codes to T45.1X5S.
• Collagenase sits with the keratolytics and codes to T49.4X5S.

The chart below puts the common ones side by side, so you can see where each one lands.

Aesthetic practices meet T45.3 more often than they expect. Hyaluronidase is the enzyme injected to dissolve hyaluronic acid filler. If a documented reaction to it was treated but left a lasting skin condition, T45.3X5S fits that later visit.

Table entries can change with each release, which CMS publishes annually. Confirm the drug in the current files rather than an old printout.

The S character starts once the reaction itself is treated

The seventh character S means sequela, a condition that results directly from an earlier injury or adverse effect. ICD-10-CM sets no time limit on it. The residual can appear weeks or even years later.

A worked example shows how the three characters differ. Picture a patient who reacts to a hyaluronidase injection and is treated for it.

Months later, the same patient returns with a skin condition the provider links to that reaction. That visit gets the skin condition code first, then T45.3X5S.

Adverse effect or poisoning? The prescription settles it

Ask one question first. Was the drug prescribed correctly and taken as directed? If yes, it’s an adverse effect. If not, you’re choosing between poisoning and underdosing codes.

Every code in this family needs a seventh character to be billable. If the note leaves intent or dosing unclear, query the provider before you choose T45.3X5_. The ICD List lookup tool shows the full T45.3 hierarchy when you need to check a neighboring code.

T45.3X5S always goes second on the claim

T45.3X5S never stands alone. The residual condition goes first, and T45.3X5S follows to explain its cause. That order comes from the ICD-10-CM guidelines for sequela, and reversing it trips payer edits.

Build the code set in three steps:

• Step 1: Code the residual condition, such as a chronic skin condition or organ-specific damage, as the first-listed diagnosis.
• Step 2: Add T45.3X5S as a secondary code to show the cause was an enzyme adverse effect.
• Step 3: Add codes for any comorbidities or complications the provider documents.

Next, check the tabular list for “Code first” or “Code also” instructions. CDC/NCHS can revise them in each annual update.

What the provider’s note has to show before you code it

The provider’s note must support four points before you assign T45.3X5S. If one is missing, the fix is a provider addendum, not a coder’s guess.

• Correct prescribing and use: The note confirms the enzyme was ordered at a therapeutic dose and taken as directed. Without this, you can’t tell an adverse effect from a poisoning.
• A causal link to the enzyme: The note ties the reaction to that specific drug, not an underlying illness or another medication.
• Sequela status: The record shows that treatment of the original reaction has ended. A note still describing acute care points to T45.3X5A instead.
• A named residual condition: “Residual effects of prior enzyme reaction” isn’t enough. The note must name the diagnosis, symptom or organ system involved.

Structured clinical note templates make this easier. They prompt the provider to record causation and status at every visit.

How a T45.3X5S claim moves from visit to payment

Medicare and Medicaid accept T45.3X5S as a valid diagnosis code. Acceptance isn’t payment, though. Coverage rules such as LCDs and NCDs apply to the service billed, and the diagnosis supports its medical necessity.

Here’s the path a typical claim takes:

1. The provider documents the residual condition and links it to the earlier enzyme reaction.
2. The coder assigns the residual condition code first, then T45.3X5S.
3. Billing staff confirm eligibility and any prior authorization for the follow-up service.
4. The claim goes to the clearinghouse as an 837P file, where format and field edits run.
5. The payer adjudicates it and returns an 835 remittance with any adjustment codes.

Step three catches sequela visits out more than you’d think. Authorization for the original enzyme treatment may not cover later care for its after-effects. Confirm it separately with the payer.

Four mistakes that send T45.3X5S claims back

When a T45.3X5S claim returns, the cause is usually one of four coding slips. The table pairs each one with its fix.

To find which slip caused a rejection, read the adjustment reason codes on the remittance. Our guide to common denial codes explains what each one means and how to respond.

Before you submit: A quick T45.3X5S checklist

Run through this list before a T45.3X5S claim leaves the practice. It takes a minute and catches each of the slips above.

• The drug appears under T45.3 in the Table of Drugs.
• The note says the enzyme was prescribed and taken correctly.
• Treatment of the original reaction has ended.
• The residual condition is named and coded first.
• T45.3X5S follows as a secondary code.
• Eligibility and any prior authorization are confirmed for this visit.

Tick all six and you’re far closer to a clean claim that pays on the first pass.

Tabular notes decide how T45.3X5S can be paired

Instructional notes in the tabular list are binding, and payer edits can enforce them automatically. For T45.3X5S, the key notes sit at the T36-T50 block level.

• Includes: The block covers the adverse effect of a correct substance properly given, plus poisoning and underdosing.
• Code first: For adverse effects, code the nature of the effect first, such as contact dermatitis (L23-L25).
• Excludes1: Toxic reaction to local anesthesia in pregnancy (O29.3-) can’t be reported with these codes.
• Excludes2: Conditions such as drug-induced immunodeficiency (D84.821) may be coded alongside when present.

The T45 category and T45.3 subcategory can carry notes of their own. Check them each October in the AAPC Codify lookup or the CDC web tool.

How claims management software keeps T45.3X5S claims clean

Sequela claims tend to break down in the handoffs between the provider’s note, the coder and the clearinghouse. Practice management software like Pabau keeps those steps in one system.

Pabau’s tools for faster claims management pre-fill the claim form from the patient record. Built-in ICD-10-CM and CPT lookup libraries let coders find T45.3X5S and the residual condition code without leaving the claim.

Pabau also checks that required claim fields are complete before you can send. US claims go out through Claim.MD, with eligibility checks and ERA remittance posting in the same workflow. You see payer responses without logging into another portal.

Send cleaner adverse effect sequela claims

Pabau pre-fills claims from the patient record and gives coders a built-in ICD-10-CM lookup. It checks required fields and submits through Claim.MD, so fewer sequela claims bounce back.

Book a demo

Conclusion

T45.3X5S is rarely the hard part of the claim. The work sits upstream, in confirming the drug is a T45.3 enzyme and that the note names what the reaction left behind.

If your team adopts one habit, make it the Table of Drugs lookup before coding. It keeps thrombolytic and digestive enzyme cases out of the wrong subcategory, and a field check won’t flag that for you.

Pabau can lighten the admin around it, from pre-filled claim forms to Claim.MD submission and remittance posting. Book a demo to see how it handles adverse effect and sequela claims for your practice.

Continue your research

Want to know what happens after you hit send? Claim.MD clearinghouse guide explains how claims are checked and routed to payers.

Unsure whether a sequela visit needs its own authorization? Prior authorization process walks through when payers require approval and how to request it.

Reading adjustment codes on returned claims? Electronic remittance advice shows how to read an 835 and post payments accurately.

Building a process for repeat denials? Denial management in healthcare sets out a workflow for tracking, fixing and preventing rejections.

Want to benchmark your billing compliance? Medical billing compliance covers the documentation and coding standards that keep claims audit-ready.

Frequently asked questions